QUALCOMM To $175? Plus Barclays Predicts $570 For This Stock

Mizuho raised the price target for QUALCOMM Incorporated (NASDAQ: QCOM) from $168 to $175. QUALCOMM shares fell 3.7% to $147.80 in pre-market trading.
  • Mizuho raised the price target for QUALCOMM Incorporated (NASDAQ:QCOM) from $168 to $175. QUALCOMM shares fell 3.7% to $147.80 in pre-market trading.
  • Barclays raised the price target on Humana Inc (NYSE:HUM) from $500 to $570. Humana shares fell 0.7% to $475.00 in pre-market trading.
  • BMO Capital cut The Sherwin-Williams Company (NYSE:SHW) price target from $274 to $251. Sherwin-Williams shares slipped 0.1% to $231.78 in pre-market trading.
  • Wells Fargo raised the price target on Rockwell Automation, Inc. (NYSE:ROK) from $189 to $213. Rockwell Automation shares fell 1.2% to $237.51 in pre-market trading.
  • BMO Capital cut price target for ServiceNow, Inc. (NYSE:NOW) from $520 to $497. ServiceNow shares fell 6.2% to $421.00 in pre-market trading.
  • Mizuho reduced the price target on Lam Research Corporation (NASDAQ:LRCX) from $675 to $650. Lam Research shares rose 1.1% to $472.94 in pre-market trading.
  • Wells Fargo cut the price target for Best Buy Co., Inc. (NYSE:BBY) from $82 to $70. Best Buy shares fell 2.9% to $72.30 in pre-market trading.
  • Raymond James lowered the price target on Visa Inc. (NYSE:V) from $281 to $262. Visa shares rose 0.1% to $210.51 in pre-market trading.
  • Wolfe Research cut the price target on Meta Platforms Inc (NASDAQ:META) from $240 to $200. Meta shares fell 4.5% to $162.00 in pre-market trading.
  • Oppenheimer raised the price target on Etsy, Inc (NASDAQ:ETSY) from $120 to $127. Etsy shares rose 6.5% to $101.75 in pre-market trading.

Don’t forget to check out our premarket coverage here .

Check out this: Alphabet Faces Several Price Target Cuts After Q2 Print, But This Analyst Disagrees

Total
0
Shares
Related Posts
Read More

Sagimet Biosciences Announces Completion Of Enrollment Of 120 Patients For Phase 3 Clinical Trial By Its Partner Ascletis Of Denifanstat Combined With Bevacizumab For Treatment Of Recurrent Glioblastoma

Sagimet Biosciences Inc. (NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic pathways, today announced that its license partner, Ascletis Bioscience

SGMT